PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34948185-7 2021 These observations were all prevented by AG490 inhibition of JAK2 activity. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 41-46 Janus kinase 2 Rattus norvegicus 61-65 34516361-7 2021 In addition, HSP70 siRNA and JAK2 inhibitor AG490 inhibited the cardioprotective effect of O3. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 44-49 Janus kinase 2 Rattus norvegicus 29-33 34943061-0 2021 Jak2 Inhibitor AG490 Improved Poststroke Central and Peripheral Inflammation and Metabolic Abnormalities in a Rat Model of Ischemic Stroke. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 15-20 Janus kinase 2 Rattus norvegicus 0-4 34943061-4 2021 Pretreatment with Jak2 inhibitor AG490 ameliorated neurological deficit, brain infarction, edema, oxidative stress, inflammation, caspase-3 activation, and Zonula Occludens-1 (ZO-1) reduction. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 33-38 Janus kinase 2 Rattus norvegicus 18-22 34354356-9 2021 In contrast, AG490 treatment impaired the effects of EA on neurological deficits, neuronal apoptosis and HIF-1alpha, EPO, p-JAK2, p-STAT5, HSP70, Bax and Bcl-2 expression. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 13-18 Janus kinase 2 Rattus norvegicus 124-128 33907034-12 2021 Furthermore, primary neurons stimulated with oxyhemoglobin were used to simulate subarachnoid hemorrhage in vitro, and the JAK2 inhibitor AG490 was used as an intervention. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 138-143 Janus kinase 2 Rattus norvegicus 123-127 35465093-7 2022 Further studies demonstrated that intrarubral pretreatment with JAK2/STAT3 inhibitor AG490 suppressed the elevations of spinal TNF-alpha, IL-1beta, and IL-6 and promoted the expressions of TGF-beta and IL-10 in IL-6-evoked tactile allodynia rats. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 85-90 Janus kinase 2 Rattus norvegicus 64-68 34335747-8 2021 Disruption of the JAK2/STAT3 pathway with AG490 significantly prevents the high glucose-induced increase in TGF-beta1, fibronectin, and collagen I. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 42-47 Janus kinase 2 Rattus norvegicus 18-22 32711244-10 2020 Additionally, western blotting revealed DOX-induced JAK2/STAT3 pathway activation, which was enhanced by fucoidan and weaken by AG490. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 128-133 Janus kinase 2 Rattus norvegicus 52-56 33519417-11 2020 Additionally, JAK2/STAT3 pathway inhibitor AG490 counteracted the protective effects of D3NB in vitro. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 43-48 Janus kinase 2 Rattus norvegicus 14-18 35248926-8 2022 JAK2/STAT3 pathway activation role in regulating microglia phenotypic polarization was further validated in vivo and in vitro by JAK2-specific inhibitor AG490 administration. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 153-158 Janus kinase 2 Rattus norvegicus 0-4 35248926-8 2022 JAK2/STAT3 pathway activation role in regulating microglia phenotypic polarization was further validated in vivo and in vitro by JAK2-specific inhibitor AG490 administration. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 153-158 Janus kinase 2 Rattus norvegicus 129-133 35248926-13 2022 After AG490 administration, the expression levels of p-JAK2, p-STAT3, iNOS, TNF-alpha, and IL-1beta in the AG490 +PQ group were significantly inhibited in vivo and in vitro compared with the PQ-only group. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 6-11 Janus kinase 2 Rattus norvegicus 55-59 32620936-10 2021 Pretreatment of NRCMs with the Jak2 inhibitor AG490 (10 microM) blocked Ang II-induced reduction in GJA1-20k expression and Cx43 gap junction formation; knockdown of Jak2 in NRCMs significantly lessened Ang II-induced cardiomyocyte hypertrophy and normalized GJA1-20k expression and Cx43 gap junction formation. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 46-51 Janus kinase 2 Rattus norvegicus 31-35 32620936-10 2021 Pretreatment of NRCMs with the Jak2 inhibitor AG490 (10 microM) blocked Ang II-induced reduction in GJA1-20k expression and Cx43 gap junction formation; knockdown of Jak2 in NRCMs significantly lessened Ang II-induced cardiomyocyte hypertrophy and normalized GJA1-20k expression and Cx43 gap junction formation. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 46-51 Janus kinase 2 Rattus norvegicus 166-170 32673665-11 2020 These effects can be reversed by AG490 which is a specific inhibitor of Jak2-Stat3 pathway. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 33-38 Janus kinase 2 Rattus norvegicus 72-76 31463567-5 2019 However, the cardioprotective effects of moderate H2O2PoC were abrogated by Janus kinase 2 (JAK2)/STAT3 inhibitor AG490 in rat hearts as well as adenovirus-delivered short hairpin RNA specific for STAT3 and the opener of mitochondrial calcium uniporter (MCU) spermine in rat cardiomyocytes. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 114-119 Janus kinase 2 Rattus norvegicus 76-90 32543312-11 2020 In addition, cotreatment with JAK2 inhibitor AG490 abolished the effects of edaravone. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 45-50 Janus kinase 2 Rattus norvegicus 30-34 31564534-11 2019 In vitro, oxidative stress was significantly reduced along with reduced intracellular calcium upon treatment with the JAK2 inhibitor, AG490. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 134-139 Janus kinase 2 Rattus norvegicus 118-122 32427806-11 2020 After treating with JAK2/STAT3 pathway inhibitor AG490, the phosphorylation of JAK2 and STAT3 was inhibited and the effects of miR-1906 on neurological score, infarct volume, brain water content, neuronal apoptosis and inflammatory factors were reversed. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 49-54 Janus kinase 2 Rattus norvegicus 20-24 32427806-11 2020 After treating with JAK2/STAT3 pathway inhibitor AG490, the phosphorylation of JAK2 and STAT3 was inhibited and the effects of miR-1906 on neurological score, infarct volume, brain water content, neuronal apoptosis and inflammatory factors were reversed. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 49-54 Janus kinase 2 Rattus norvegicus 79-83 32832009-6 2020 We used the JAK2-specific inhibitor AG490 to explore the underlying mechanism. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 36-41 Janus kinase 2 Rattus norvegicus 12-16 32832009-12 2020 Upon treatment with JAK2-specific inhibitor AG490, intestinal injury was balanced. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 44-49 Janus kinase 2 Rattus norvegicus 20-24 32380573-5 2020 Administration of either the JAK2 antagonist AG490 or the ERK antagonist PD98059 to the RN of rats with SNI remarkably increased the paw withdrawal threshold (PWT) and inhibited the up-regulations of local TNF-alpha and IL-1beta. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 45-50 Janus kinase 2 Rattus norvegicus 29-33 32395527-5 2020 Rats in group AG490 received 10 mg/kg of the Janus kinase 2 (JAK2) inhibitor, AG490, 30 min before anesthesia. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 14-19 Janus kinase 2 Rattus norvegicus 45-59 32395527-5 2020 Rats in group AG490 received 10 mg/kg of the Janus kinase 2 (JAK2) inhibitor, AG490, 30 min before anesthesia. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 14-19 Janus kinase 2 Rattus norvegicus 61-65 31368573-4 2019 AG490, a JAK2 inhibitor, partially ameliorated these effect while Losartan, an AT1 inhibitor completely abolished collagen synthesis. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 0-5 Janus kinase 2 Rattus norvegicus 9-13 30070334-6 2018 JAK2 inhibitor (AG490, 3 mg/kg) was injected before EP. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 16-21 Janus kinase 2 Rattus norvegicus 0-4 30412649-11 2019 Moreover, the p38 mitogen-activated protein kinase (MAPK) inhibitor SB203580, the c-Jun N-terminal kinase (JNK) inhibitor SP600125 and the Janus-activated kinase (JAK)2 inhibitor AG490 suppressed Ang II-induced differentiation of BM-MSCs into keratinocytes. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 179-184 Janus kinase 2 Rattus norvegicus 139-168 30216497-7 2018 Further studies demonstrated that injection of the JAK2 antagonist AG490 or JNK antagonist SP600125 into the RN 30 min prior to the administration of rrIL-1beta could completely prevent IL-1beta-evoked tactile allodynia, while injection of the ERK antagonist PD98059, p38 MAPK antagonist SB203580, or NF-kappaB antagonist PDTC did not affect IL-1beta-evoked tactile allodynia. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 67-72 Janus kinase 2 Rattus norvegicus 51-55 30657573-8 2019 JAK2 inhibitor AG490 markedly decreased the phosphorylation of JAK2 and STAT3 in hippocampal neurons in the model group (p<0.05). alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 15-20 Janus kinase 2 Rattus norvegicus 0-4 30657573-8 2019 JAK2 inhibitor AG490 markedly decreased the phosphorylation of JAK2 and STAT3 in hippocampal neurons in the model group (p<0.05). alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 15-20 Janus kinase 2 Rattus norvegicus 63-67 30070334-11 2018 Treatment with AG490 abolished the cardioprotective effects and the enhanced phosphorylations of JAK2 and STAT3 induced by EP. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 15-20 Janus kinase 2 Rattus norvegicus 97-101 28239766-11 2017 The Jak2 inhibitor, AG490 inhibited this interaction and decreased the active caspase3 expression as well as promoted the functional recovery. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 20-25 Janus kinase 2 Rattus norvegicus 4-8 29183675-5 2018 Microinjection of JAK2 inhibitor AG490, ERK inhibitor PD98059 and also JNK inhibitor SP600125 into the RN significantly increased the paw withdrawal threshold (PWT) and alleviated SNI-induced mechanical allodynia. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 33-38 Janus kinase 2 Rattus norvegicus 18-22 27426446-9 2017 Transfection of cultured rat NP cells with STAT1 or STAT3 lentiviral short hairpin RNAs or treatment with the JAK2 inhibitor AG490 significantly reduced IL-17-stimulated VEGF expression. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 125-130 Janus kinase 2 Rattus norvegicus 110-114 27748739-9 2017 The JAK2 inhibitor AG490 given systemically or into the OFC at the time of ketamine injection prevented its beneficial effect on reversal learning. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 19-24 Janus kinase 2 Rattus norvegicus 4-8 28392989-6 2017 At the beginning of reperfusion, 2.4% sevoflurane alone or in combination with AG490 (a JAK2 selective inhibitor) was used as a postconditioning treatment. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 79-84 Janus kinase 2 Rattus norvegicus 88-92 27848055-6 2017 In addition, we observed that knockdown of KLF11 elevated the expression of p-JAK2 and p-STAT3 in H9c2, and AG490, a selective inhibitor of JAK2/STAT3 abrogated the potential roles of KLF11 in cell apoptosis and mitochondrial damage. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 108-113 Janus kinase 2 Rattus norvegicus 140-144 29489692-4 2018 Some cultures were also treated with AG490, an inhibitor of the EPO-EPO receptor (EpoR) pathway mediator Janus kinase 2 (JAK2). alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 37-42 Janus kinase 2 Rattus norvegicus 105-119 29489692-4 2018 Some cultures were also treated with AG490, an inhibitor of the EPO-EPO receptor (EpoR) pathway mediator Janus kinase 2 (JAK2). alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 37-42 Janus kinase 2 Rattus norvegicus 121-125 29039526-11 2017 Treatment with AG490, an inhibitor of JAK2-STAT3, partially attenuated the pro-inflammatory and pro-apoptotic effects of IL-23 (P<0.05). alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 15-20 Janus kinase 2 Rattus norvegicus 38-42 29171438-6 2017 Additionally, preincubation with either JAK2 inhibitor AG490 or PI3K inhibitor LY294002 blocked the neuroprotective effect of ciliary neurotrophic factor. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 55-60 Janus kinase 2 Rattus norvegicus 40-44 27998796-11 2017 Consistently, pretreatment with JAK2/STAT3 pathway inhibitor AG490, decreased the levels of MDA, TNFalpha, S100beta, NSE and increased activity of SOD, IL-10, and attenuated the expression of JAK2 and STAT3. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 61-66 Janus kinase 2 Rattus norvegicus 32-36 27998796-11 2017 Consistently, pretreatment with JAK2/STAT3 pathway inhibitor AG490, decreased the levels of MDA, TNFalpha, S100beta, NSE and increased activity of SOD, IL-10, and attenuated the expression of JAK2 and STAT3. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 61-66 Janus kinase 2 Rattus norvegicus 192-196 29210652-5 2017 Pharmacological suppression of JAK2 by its inhibitor AG490 robustly protected against tissue damage, attenuated JAK2/STAT3 signaling and inflammatory responses. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 53-58 Janus kinase 2 Rattus norvegicus 31-35 26385087-6 2017 In two different cirrhosis models (BDL, CCl4) in rats, the acute haemodynamic effect of the JAK2 inhibitor AG490 was assessed using microsphere technique and isolated liver perfusion experiments. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 107-112 Janus kinase 2 Rattus norvegicus 92-96 29210652-5 2017 Pharmacological suppression of JAK2 by its inhibitor AG490 robustly protected against tissue damage, attenuated JAK2/STAT3 signaling and inflammatory responses. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 53-58 Janus kinase 2 Rattus norvegicus 112-116 29210652-7 2017 Interestingly, JAK2 inhibitor AG490 significantly inhibited pancreas necrosis and systemic inflammation in animals fed with high fat or chow-diet, but did not affect STAT3 signaling. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 30-35 Janus kinase 2 Rattus norvegicus 15-19 26806299-11 2016 Pretreatment with BBR also activated the JAK2/STAT3 signaling pathway in heart tissues, and co-treatment with AG490, a specific JAK2/STAT3 inhibitor, blocked not only the protective effects of BBR, but also the inhibition of BBR on MI/R-induced ER stress. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 110-115 Janus kinase 2 Rattus norvegicus 41-45 27754827-3 2016 This study investigated the effect of the late inflammatory factor high mobility group box 1 (HMGB1) on the activation of JAK2/STAT3 in pancreatic acinar cells and the inhibitory effects of AG490 (a JAK2 inhibitor) and rapamycin (a STAT3 inhibitor) on this pathway. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 190-195 Janus kinase 2 Rattus norvegicus 199-203 26666444-7 2016 PTEN inhibition/gene knockdown mediated restoration of IPostC/HPostC cardioprotection was completely reversed by the PI3K inhibitor wortmannin, and partially reversed by the JAK2 inhibitor AG490. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 189-194 Janus kinase 2 Rattus norvegicus 174-178 26806299-11 2016 Pretreatment with BBR also activated the JAK2/STAT3 signaling pathway in heart tissues, and co-treatment with AG490, a specific JAK2/STAT3 inhibitor, blocked not only the protective effects of BBR, but also the inhibition of BBR on MI/R-induced ER stress. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 110-115 Janus kinase 2 Rattus norvegicus 128-132 26649078-3 2015 Groups of rats were treated with rhEPO or CEPO before induction of epilepsy, whereas additional rats were given a caudal vein injection of AG490, a selective inhibitor of Janus kinase 2 (JAK2). alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 139-144 Janus kinase 2 Rattus norvegicus 171-185 27450794-10 2016 The increased levels of IL-6 and TNF-alpha caused by high-dose linoleic acid were attenuated by JAK2 inhibitor AG490. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 111-116 Janus kinase 2 Rattus norvegicus 96-100 26807029-9 2016 Furthermore, JAK-2 inhibitor AG490, MAPK kinase inhibitor PD98059, and CaMKII inhibitor KN-62 inhibited the tolerance, but PI-3 kinase inhibitor LY294,002 did not. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 29-34 Janus kinase 2 Rattus norvegicus 13-18 26405549-4 2015 The role of this pathway was investigated using the JAK2 inhibitor, AG490, in a rat model of inflammatory pain. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 68-73 Janus kinase 2 Rattus norvegicus 52-56 26405549-13 2015 Therefore, we suggest that AG490 produces these effects by blocking JAK2 signaling. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 27-32 Janus kinase 2 Rattus norvegicus 68-72 26649078-3 2015 Groups of rats were treated with rhEPO or CEPO before induction of epilepsy, whereas additional rats were given a caudal vein injection of AG490, a selective inhibitor of Janus kinase 2 (JAK2). alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 139-144 Janus kinase 2 Rattus norvegicus 187-191 24836854-7 2014 Blockade of JAK2-STAT3 signaling with intrathecal administration of the JAK2 inhibitor AG490 or the STAT3 inhibitor S3I-201 clearly reduced mechanical allodynia and the upregulation of pro-inflammatory cytokines in CCI rats. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 87-92 Janus kinase 2 Rattus norvegicus 12-16 25637451-2 2015 This study aimed to explore the function of JAK2/STAT3 signalling in portal hypertension and estimate the potential therapeutic effect of treatment with the specific inhibitor AG490. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 176-181 Janus kinase 2 Rattus norvegicus 44-48 26261556-2 2015 This study aimed to observe the effects of JAK2 inhibitor AG490 on the brain injury and inflammatory responses of rats with systemic heatstroke. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 58-63 Janus kinase 2 Rattus norvegicus 43-47 26261556-6 2015 However, the JAK2 inhibitor AG490 was significantly attenuated the brain injury and inflammatory responses induced by heatstroke in rats. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 28-33 Janus kinase 2 Rattus norvegicus 13-17 26261556-8 2015 These findings suggest that AG490 may prevent the occurrence of heatstroke via inhibiting the JAK2/STAT3 pathway and the systemic inflammatory responses. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 28-33 Janus kinase 2 Rattus norvegicus 94-98 25023896-12 2015 AG490, a specific Jak2 inhibitor, attenuated the protective effects of TAT-Ngb. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 0-5 Janus kinase 2 Rattus norvegicus 18-22 25796004-6 2015 All of these protective effects of Elatoside C were partially abolished by the PI3K/Akt inhibitor LY294002, ERK1/2 inhibitor PD98059, and JAK2/STAT3 inhibitor AG490. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 159-164 Janus kinase 2 Rattus norvegicus 138-142 25731682-7 2015 These effects were abolished by scavenging ROS with N-(2-mercaptopropionyl)-glycine (2-MPG) and/or by inhibiting JAK2 with AG490 during the early reperfusion. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 123-128 Janus kinase 2 Rattus norvegicus 113-117 25088002-10 2014 Pretreatment of the cells with AG490, a JAK2 inhibitor, markedly inhibited Ang II-induced STAT3 phosphorylation on Tyr705 and fibronectin expression. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 31-36 Janus kinase 2 Rattus norvegicus 40-44 25105067-10 2014 Conversely, pretreatment with JAK2/STAT3 pathway inhibitor AG490 or stattic inhibited propofol-induced AKT phosphorylation. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 59-64 Janus kinase 2 Rattus norvegicus 30-34 24836854-7 2014 Blockade of JAK2-STAT3 signaling with intrathecal administration of the JAK2 inhibitor AG490 or the STAT3 inhibitor S3I-201 clearly reduced mechanical allodynia and the upregulation of pro-inflammatory cytokines in CCI rats. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 87-92 Janus kinase 2 Rattus norvegicus 72-76 23516544-6 2013 Under the treatment with AG490 (a JAK2 inhibitor), protein levels of JAK2, STAT3 and PCNA, morphological changes of artery, phenotypic change of VSMCs, and re-endothelialization were measured by Western blotting, H&E, Q-PCR, and Evans blue staining respectively. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 25-30 Janus kinase 2 Rattus norvegicus 34-38 24055641-9 2013 The induction of MCP-1 and iNOS was inhibited by both the Jak2/Stat3 inhibitor AG490 and RGE in Helicobacter pylori-infected cells. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 79-84 Janus kinase 2 Rattus norvegicus 58-62 23764464-4 2013 In this study, we used AG490, a specific inhibitor of the signaling pathway involving the Janus Kinase 2 (JAK2)/Signal Transducers and Activators of Transcription 3 (STAT3) signaling molecules and suramin, a potent inhibitor of vascular endothelial growth factor (VEGF), to investigate the mechanisms of SMND-309. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 23-28 Janus kinase 2 Rattus norvegicus 90-104 23764464-4 2013 In this study, we used AG490, a specific inhibitor of the signaling pathway involving the Janus Kinase 2 (JAK2)/Signal Transducers and Activators of Transcription 3 (STAT3) signaling molecules and suramin, a potent inhibitor of vascular endothelial growth factor (VEGF), to investigate the mechanisms of SMND-309. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 23-28 Janus kinase 2 Rattus norvegicus 106-110 23747931-8 2013 The PI3K inhibitor wortmannin and Jak2 inhibitor AG490 abolished the protection of NAC and ALP. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 49-54 Janus kinase 2 Rattus norvegicus 34-38 23759023-12 2013 Either dexmedetomidine or AG490 inhibited the phosphorylations of JAK2 and its downstream molecule STAT1 and STAT3, accompanied by down-regulation the expression of cleaved caspase 3, ICAM-1 and MCP-1 proteins, and significantly ameliorated renal I/R injury. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 26-31 Janus kinase 2 Rattus norvegicus 66-70 23516544-6 2013 Under the treatment with AG490 (a JAK2 inhibitor), protein levels of JAK2, STAT3 and PCNA, morphological changes of artery, phenotypic change of VSMCs, and re-endothelialization were measured by Western blotting, H&E, Q-PCR, and Evans blue staining respectively. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 25-30 Janus kinase 2 Rattus norvegicus 69-73 22948409-10 2012 However, H2S-mediated protection was abolished by AG-490, the JAK2 inhibitor. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 50-56 Janus kinase 2 Rattus norvegicus 62-66 22403794-7 2012 The PRL-induced changes in I(sc) in both distal and proximal colon were abolished by JAK2 inhibitor AG490, but not BAPTA-AM, the Ca(2+) chelating agent, or phosphatidylinositol 3-kinase inhibitor wortmannin. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 100-105 Janus kinase 2 Rattus norvegicus 85-89 21470923-9 2011 Importantly, exogenous recombinant rat IL-6 can also induce phosphorylation of STAT3 concomitant with GFAP expression while JAK2 specific inhibitor AG490 could effectively block both cholera toxin- and IL-6-induced GFAP expression. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 148-153 Janus kinase 2 Rattus norvegicus 124-128 24058756-5 2012 The Ang II-mediated phosphorylation of both JAK2 and STAT3 was blocked by AG490, a selective JAK2 inhibitor. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 74-79 Janus kinase 2 Rattus norvegicus 44-48 24058756-5 2012 The Ang II-mediated phosphorylation of both JAK2 and STAT3 was blocked by AG490, a selective JAK2 inhibitor. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 74-79 Janus kinase 2 Rattus norvegicus 93-97 23071812-10 2012 The expression of MSM-induced IGF-1R and GHR was inhibited by AG490, a Jak2 kinase inhibitor. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 62-67 Janus kinase 2 Rattus norvegicus 71-75 21509626-3 2011 TREATMENT: AR42J cells were treated with an NADPH oxidase inhibitor diphenyleneiodonium (DPI) or a Jak2 inhibitor AG490. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 114-119 Janus kinase 2 Rattus norvegicus 99-103 21596098-5 2011 Moreover, we assessed the neurological recovery (using Neurological Severity Scores (NSS)) of rats under the pretreatment of a JAK2 inhibitor, AG490. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 143-148 Janus kinase 2 Rattus norvegicus 127-131 19304867-5 2010 Pre-treatment with a JAK2 inhibitor AG490, significantly attenuated the olanzapine-induced reductions in serotonin 2A receptor-stimulated phospholipase C activity and prevented the olanzapine-induced increases in RGS7 mRNA and protein levels. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 36-41 Janus kinase 2 Rattus norvegicus 21-25 19748527-6 2010 The JAK2 inhibitor, AG490 (50 microM), prevented Ang II JAK2 phosphorylation. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 20-25 Janus kinase 2 Rattus norvegicus 4-8 19748527-6 2010 The JAK2 inhibitor, AG490 (50 microM), prevented Ang II JAK2 phosphorylation. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 20-25 Janus kinase 2 Rattus norvegicus 56-60 18636982-8 2008 STAT3 pathway blockade with Janus kinase 2 inhibitor AG490 attenuated both mechanical allodynia and thermal hyperalgesia in SNL rats. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 53-58 Janus kinase 2 Rattus norvegicus 28-42 18710787-4 2008 AG490, a JAK inhibitor, markedly reduced activation of JAK2 and STAT3 in thrombin-treated microglia. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 0-5 Janus kinase 2 Rattus norvegicus 55-59 18719678-10 2008 The Janus kinase 2 (JAK2) inhibitor AG490, the mitogen-activated protein kinase (MAPK) inhibitor SB203580, and the nitric oxide synthase (NOS) inhibitor L-NAME abrogated leptin-induced cardiomyocyte contractile response in low-fat diet group without affecting the high-fat diet group. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 36-41 Janus kinase 2 Rattus norvegicus 4-18 18719678-10 2008 The Janus kinase 2 (JAK2) inhibitor AG490, the mitogen-activated protein kinase (MAPK) inhibitor SB203580, and the nitric oxide synthase (NOS) inhibitor L-NAME abrogated leptin-induced cardiomyocyte contractile response in low-fat diet group without affecting the high-fat diet group. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 36-41 Janus kinase 2 Rattus norvegicus 20-24 16934228-0 2006 Suppression of IL-1beta expression by the Jak 2 inhibitor AG490 in cerulein-stimulated pancreatic acinar cells. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 58-63 Janus kinase 2 Rattus norvegicus 42-47 19099985-12 2008 rhG-CSF significantly attenuated CME induced changes and cotreatment with JAK2 inhibitor AG490 abolished the effects of rhG-CSF. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 89-94 Janus kinase 2 Rattus norvegicus 74-78 17519522-6 2007 However, the PRL-induced corticosterone and progesterone releases were significantly reduced by treatment with AG490, a specific Janus kinase 2 (Jak2) inhibitor. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 111-116 Janus kinase 2 Rattus norvegicus 129-143 17519522-6 2007 However, the PRL-induced corticosterone and progesterone releases were significantly reduced by treatment with AG490, a specific Janus kinase 2 (Jak2) inhibitor. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 111-116 Janus kinase 2 Rattus norvegicus 145-149 17466927-6 2007 AGE-induced Hsp70 was attenuated by AG-490 (a JAK2 inhibitor) and N-acetylcysteine. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 36-42 Janus kinase 2 Rattus norvegicus 46-50 16923154-6 2006 Intracerebroventricular infusion of rats with AG490 (a JAK2 phosphorylation inhibitor) prevented the post-ischemic JAK2 and STAT3 phosphorylation and significantly decreased the infarct volume, number of apoptotic cells and neurological deficits, compared to vehicle control. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 46-51 Janus kinase 2 Rattus norvegicus 55-59 16923154-6 2006 Intracerebroventricular infusion of rats with AG490 (a JAK2 phosphorylation inhibitor) prevented the post-ischemic JAK2 and STAT3 phosphorylation and significantly decreased the infarct volume, number of apoptotic cells and neurological deficits, compared to vehicle control. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 46-51 Janus kinase 2 Rattus norvegicus 115-119 18083188-10 2008 Cardioprotection by Gd was abolished by inhibition of JAK-2 with AG-490, of p42/44 MAPK with PD98059 or of K(ATP) channels with glibenclamide. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 65-71 Janus kinase 2 Rattus norvegicus 54-59 18031608-13 2007 These high glucose-induced changes were suppressed by fluvastatin, as well as AG490, a JAK2 inhibitor. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 78-83 Janus kinase 2 Rattus norvegicus 87-91 17607690-0 2007 Exposure of glia to pro-oxidant agents revealed selective Stat1 activation by H2O2 and Jak2-independent antioxidant features of the Jak2 inhibitor AG490. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 147-152 Janus kinase 2 Rattus norvegicus 132-136 16597920-5 2006 hGH caused tyrosine phosphorylation of Janus kinase (JAK)2 and c-Src, events inhibited by the JAK2 inhibitor AG490 or the Src kinase inhibitor PP2. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 109-114 Janus kinase 2 Rattus norvegicus 53-58 16597920-5 2006 hGH caused tyrosine phosphorylation of Janus kinase (JAK)2 and c-Src, events inhibited by the JAK2 inhibitor AG490 or the Src kinase inhibitor PP2. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 109-114 Janus kinase 2 Rattus norvegicus 94-98 16257270-10 2005 To eliminate the possibility of clonal artifact in the DN cells, wild type RASM cells were treated with the Jak2 pharmacological inhibitor, AG490. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 140-145 Janus kinase 2 Rattus norvegicus 108-112 15932931-10 2005 The stimulatory effect of aldosterone on ACE mRNA expression was completely blocked by a protein tyrosine kinase inhibitor (genistein) and JAK2 inhibitor (AG490), partially by Src kinase inhibitor (PP2) and epidermal growth factor receptor kinase inhibitor (AG1478), but not by platelet-derived growth factor receptor kinase inhibitor (AG1296). alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 155-160 Janus kinase 2 Rattus norvegicus 139-143 16269269-4 2005 Activation of these pro-apoptotic pathways was blocked by the Jak2 pharmacological inhibitor, Tyrphostin AG490. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 94-110 Janus kinase 2 Rattus norvegicus 62-66 14657181-1 2003 We showed recently that nicotine activates the growth-promoting enzyme Janus kinase 2 (JAK2) in PC12 cells and that preincubation of these cells with the JAK2-specific inhibitor AG-490 blocked the nicotine-induced neuroprotection against beta-amyloid (1-42) [Abeta (1-42)]. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 178-184 Janus kinase 2 Rattus norvegicus 71-85 15770649-5 2005 We also found that AGE (150 microg/ml) increased angiotensinogen protein at 2 days, which was attenuated by AG-490 (a JAK2 inhibitor). alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 108-114 Janus kinase 2 Rattus norvegicus 118-122 15601754-9 2005 5-HT (10(-6) M) treatment resulted in increased cell proliferation and increased DNA synthesis, which were inhibited by the JAK2 inhibitor AG490. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 139-144 Janus kinase 2 Rattus norvegicus 124-128 15721267-8 2005 A p38 MAP kinase inhibitor SB203580 significantly inhibited leptin-induced hypertrophy, AG490 (a JAK2 inhibitor) partially inhibited it, and other MAP kinase inhibitors, PD98059 (an ERK inhibitor) and SP600125 (a JNK inhibitor), had no effect. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 88-93 Janus kinase 2 Rattus norvegicus 97-101 15601621-6 2005 Inhibition of the tyrosine kinase Jak2, with the specific inhibitor AG490, abrogated this effect. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 68-73 Janus kinase 2 Rattus norvegicus 34-38 16138568-5 2005 These effects of caffeic acid were consistent with the inhibition of the proliferation of VSMCs by DPI, an NADPH oxidase inhibitor, and by AG-490, a JAK2 inhibitor. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 139-145 Janus kinase 2 Rattus norvegicus 149-153 15389880-9 2004 AG-490 (JAK2 inhibitor) abrogated AGE-induced leptin mRNA and protein expression at 2-3 days. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 0-6 Janus kinase 2 Rattus norvegicus 8-12 15159394-6 2004 However, apoptosis was prevented by either the expression of a dominant negative Jak2 protein or by the Jak2 pharmacological inhibitor AG490. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 135-140 Janus kinase 2 Rattus norvegicus 104-108 15659221-12 2005 However, we found evidence suggesting that AG490 reduces oxidative stress induced by H(2)O(2), which further shows that H(2)O(2) and/or derived reactive oxygen species directly activate Jak2/Stat1, but masks the actual involvement of this pathway in H(2)O(2)-induced cell death. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 43-48 Janus kinase 2 Rattus norvegicus 186-190 15256805-7 2004 50 microM of AG490, a specific JAK 2 inhibitor, partially inhibited STAT 3 activation and MCP-1 production, with near complete inhibition of DNA synthesis. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 13-18 Janus kinase 2 Rattus norvegicus 31-36 14678947-7 2004 Groups of rats were given captopril (75-85 mg x kg(-1) x day(-1)), candesartan (10 mg x kg(-1) x day(-1)), or the JAK2 inhibitor AG-490 (5 mg x kg(-1) x day(-1)) for the study"s duration. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 129-135 Janus kinase 2 Rattus norvegicus 114-118 14969715-7 2004 Pretreatment with a JAK2 inhibitor AG490 (10 nM) and a MEK inhibitor PD98059 (10 microM) suppressed rhGH-induced rise in mtTF1 mRNA levels of VSMC to the control levels. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 35-40 Janus kinase 2 Rattus norvegicus 20-24 14657181-1 2003 We showed recently that nicotine activates the growth-promoting enzyme Janus kinase 2 (JAK2) in PC12 cells and that preincubation of these cells with the JAK2-specific inhibitor AG-490 blocked the nicotine-induced neuroprotection against beta-amyloid (1-42) [Abeta (1-42)]. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 178-184 Janus kinase 2 Rattus norvegicus 87-91 14657181-1 2003 We showed recently that nicotine activates the growth-promoting enzyme Janus kinase 2 (JAK2) in PC12 cells and that preincubation of these cells with the JAK2-specific inhibitor AG-490 blocked the nicotine-induced neuroprotection against beta-amyloid (1-42) [Abeta (1-42)]. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 178-184 Janus kinase 2 Rattus norvegicus 154-158 12470866-4 2002 The addition of the Jak2 inhibitor AG490 (50 microM for 48 h) blocked the EPO effect. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 35-40 Janus kinase 2 Rattus norvegicus 20-24 11755929-7 2002 Tyrphostin B42 (AG490), a Jak-2 tyrosine kinase inhibitor, similarly blocked the cytokine-induced NOx production, iNOS expression and its promoter activity without affecting NF-kappaB-dependent transcription. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 0-14 Janus kinase 2 Rattus norvegicus 26-31 12451129-9 2002 Cultured neurons express EpoR, and the Janus kinase-2 (JAK-2) inhibitor AG490 abolished EPO-induced tolerance against OGD. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 72-77 Janus kinase 2 Rattus norvegicus 39-53 12451129-9 2002 Cultured neurons express EpoR, and the Janus kinase-2 (JAK-2) inhibitor AG490 abolished EPO-induced tolerance against OGD. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 72-77 Janus kinase 2 Rattus norvegicus 55-60 11684565-8 2001 Meanwhile, AGE induced STAT5 protein-DNA binding activity, which was reversed by AG-490 (a specific JAK2 inhibitor) and STAT5 decoy oligodeoxynucleotide (ODN). alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 81-87 Janus kinase 2 Rattus norvegicus 100-104 11682625-4 2001 In primary luteinized granulosa cells, the general tyrosine kinase inhibitors, genistein and AG18, and the Jak2 inhibitor, AG490, prevented PRL stimulation of ERalpha mRNA levels, suggesting that PRL signaling to the ERalpha gene requires Jak2 activity. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 123-128 Janus kinase 2 Rattus norvegicus 107-111 11682625-4 2001 In primary luteinized granulosa cells, the general tyrosine kinase inhibitors, genistein and AG18, and the Jak2 inhibitor, AG490, prevented PRL stimulation of ERalpha mRNA levels, suggesting that PRL signaling to the ERalpha gene requires Jak2 activity. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 123-128 Janus kinase 2 Rattus norvegicus 239-243 11335106-3 2001 In contrast, the JAK2 inhibitor AG490 inhibited the IL-5-induced prolongation of eosinophil survival. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 32-37 Janus kinase 2 Rattus norvegicus 17-21 11457752-7 2001 Hearts treated with the JAK 2 inhibitor tyrphostin AG490 showed a reduction in myocardial infarct size and in number of cardiomyocytes undergoing apoptosis. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 51-56 Janus kinase 2 Rattus norvegicus 24-29 11681720-8 2001 GH induced tyrosine phosphorylation of EGF receptor and JAK2 in cardiac myocytes, and an EGF receptor inhibitor tyrphostin AG1478 and a JAK2 inhibitor tyrphostin B42 completely inhibited GH-induced ERK activation. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 151-165 Janus kinase 2 Rattus norvegicus 56-60 11681720-8 2001 GH induced tyrosine phosphorylation of EGF receptor and JAK2 in cardiac myocytes, and an EGF receptor inhibitor tyrphostin AG1478 and a JAK2 inhibitor tyrphostin B42 completely inhibited GH-induced ERK activation. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 151-165 Janus kinase 2 Rattus norvegicus 136-140 10884366-9 2000 Additionally, a Jak2 inhibitor, AG490, blocked the Ang II-induced Stat3 phosphorylation. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 32-37 Janus kinase 2 Rattus norvegicus 16-20 11231909-5 2001 Inhibition of JAK2 activity with AG-490 partially inhibited H(2)O(2)-induced ERK2 activity, suggesting that JAK2 is upstream of the Ras/Raf/mitogen-activated protein kinase-ERK/ERK mitogenic pathway. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 33-39 Janus kinase 2 Rattus norvegicus 14-18 11231909-5 2001 Inhibition of JAK2 activity with AG-490 partially inhibited H(2)O(2)-induced ERK2 activity, suggesting that JAK2 is upstream of the Ras/Raf/mitogen-activated protein kinase-ERK/ERK mitogenic pathway. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 33-39 Janus kinase 2 Rattus norvegicus 108-112 11162585-8 2001 Blockade of JAK2 with AG490 abolished this complex formation; therefore, JAK2 may be the kinase responsible for SHC phosphorylation. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 22-27 Janus kinase 2 Rattus norvegicus 12-16 11162585-8 2001 Blockade of JAK2 with AG490 abolished this complex formation; therefore, JAK2 may be the kinase responsible for SHC phosphorylation. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 22-27 Janus kinase 2 Rattus norvegicus 73-77 11180401-7 2001 AGE-induced type I collagen production and JAK2-STAT1/STAT3 activation were decreased by AG-490 (a specific JAK2 inhibitor), antisense RAGE ODN and captopril. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 89-95 Janus kinase 2 Rattus norvegicus 43-47 11180401-7 2001 AGE-induced type I collagen production and JAK2-STAT1/STAT3 activation were decreased by AG-490 (a specific JAK2 inhibitor), antisense RAGE ODN and captopril. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 89-95 Janus kinase 2 Rattus norvegicus 108-112 11110778-8 2000 Inhibition of JAK2 by its inhibitor AG490 (10 micromol/L) blocked not only JAK2 activation but also IL-6 synthesis. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 36-41 Janus kinase 2 Rattus norvegicus 14-18 11110778-8 2000 Inhibition of JAK2 by its inhibitor AG490 (10 micromol/L) blocked not only JAK2 activation but also IL-6 synthesis. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 36-41 Janus kinase 2 Rattus norvegicus 75-79 10867506-4 2000 In contrast, the JAK2 inhibitor AG490 inhibited the IL-5-induced prolongation of eosinophil survival. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 32-37 Janus kinase 2 Rattus norvegicus 17-21 11710966-11 2001 Treatment with the JAK2 inhibitor AG490 induced apoptosis in NRP-152, but not NRP-154 cells. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 34-39 Janus kinase 2 Rattus norvegicus 19-23 10601634-3 1999 cMG1/ERF-1 expression was inhibited by AG490 (JAK2 inhibitor) and genistein, but was unaffected by PD98059 or wortmannin. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 39-44 Janus kinase 2 Rattus norvegicus 46-50 10585879-8 1999 Pretreatment with AG-490, a specific JAK-2 inhibitor, and SpcAMP, a cAMP agonist, prevented the insulin-mediated increase in (i) JAK-2 kinase activity, (ii) PP-2A tyrosine phosphorylation, (iii) PP-2A inactivation and restored the enzyme activity to control levels, and (iv) PP-2A and JAK-2-associated PI-3K activity. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 18-24 Janus kinase 2 Rattus norvegicus 37-42 10585879-8 1999 Pretreatment with AG-490, a specific JAK-2 inhibitor, and SpcAMP, a cAMP agonist, prevented the insulin-mediated increase in (i) JAK-2 kinase activity, (ii) PP-2A tyrosine phosphorylation, (iii) PP-2A inactivation and restored the enzyme activity to control levels, and (iv) PP-2A and JAK-2-associated PI-3K activity. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 18-24 Janus kinase 2 Rattus norvegicus 129-134 10585879-8 1999 Pretreatment with AG-490, a specific JAK-2 inhibitor, and SpcAMP, a cAMP agonist, prevented the insulin-mediated increase in (i) JAK-2 kinase activity, (ii) PP-2A tyrosine phosphorylation, (iii) PP-2A inactivation and restored the enzyme activity to control levels, and (iv) PP-2A and JAK-2-associated PI-3K activity. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 18-24 Janus kinase 2 Rattus norvegicus 129-134 11601336-8 1999 Moreover, tyrphostin B42, an inhibitor of JAK2 suppressed GH-induced phosphorylation of EGF receptor as well as GH-induced activation of ERKs in cardiac myocytes. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 10-24 Janus kinase 2 Rattus norvegicus 42-46 10462502-8 1999 The expression suppression was reversed by either a MAPKK inhibitor PD98059 or a Jak-2 inhibitor AG-490. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 97-103 Janus kinase 2 Rattus norvegicus 81-86 10203355-5 1999 Cells were stimulated with TNF-alpha or LPS plus IFN-gamma in the presence of NF-kappaB inhibitors, herbimycin A (HerA), or the more specific JAK2 inhibitor AG490. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 157-162 Janus kinase 2 Rattus norvegicus 142-146 9299374-10 1997 Selective inhibition of Jak2 kinase with AG-490 blocked formation of angiotensin II induced SIF complexes, suggesting that Jak2 kinase is required for cardiomyocyte SIF induction. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 41-47 Janus kinase 2 Rattus norvegicus 24-28 9602424-13 1998 Selective inhibition of Jak2 kinase with AG-490 blocked formation of prolactin-inducing factor (PIF) complexes by Ang II, suggesting that Jak2 kinase was required for the tyrosine phosphorylation of Stat5 in cardiac myocytes. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 41-47 Janus kinase 2 Rattus norvegicus 24-28 33793419-5 2021 Treatment with the JAK2 inhibitor AG490 reversed BMSC-CM-induced activation of the JAK2/STAT4 pathway. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 34-39 Janus kinase 2 Rattus norvegicus 19-23 33793419-5 2021 Treatment with the JAK2 inhibitor AG490 reversed BMSC-CM-induced activation of the JAK2/STAT4 pathway. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 34-39 Janus kinase 2 Rattus norvegicus 83-87 26628981-5 2015 AG490, a JAK2 inhibitor, was utilized to throw light upon the underlying mechanism. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 0-5 Janus kinase 2 Rattus norvegicus 9-13 26628981-8 2015 The results of western blot indicated that Cur enhanced the expression of p-JAK2 and p-STAT3, which was abolished by AG490 administration. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 117-122 Janus kinase 2 Rattus norvegicus 76-80